Page 47 - CIBERES-2015-eng

Most relevant scientific articles
Research Groups
gaLie n., BarBera J.a., Frost a.e., ghoFrani h.-a., hoeP- er M.M., MCLaughLin v.v. et aL. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. New England Journal of Medicine. 2015;373(9):834-844.
gaLiè n, huMBert M, vaChiery JL, giBBs s, Lang i, tor- BiCKi a et aL. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hy- pertension of the European Society of Cardiology (ESC)
DoMinguez-FanDos D., vaLDes C., Ferrer e., Puig-Pey r., BLanCo i., tura-CeiDe o. et aL. Sildenafil in a cigarette smoke-induced model of COPD in the Guinea-pig. Europe- an Respiratory Journal. 2015;46(2):346-354.
agusti a., anto J.M., auFFray C., BarBe F., Barreiro e., DorCa J. et aL. Personalized respiratory medicine: Ex- ploring the horizon, addressing the issues: Summary of a BRN-AJRCCM workshop held in Barcelona on June 12, 2014. American Journal of Respiratory and Critical Care
and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Car- diology (AEPC), International Society for Heart and Lung Transplantation (ISHLT).The European respiratory journal. 2015;46(4):903-75.
Highlights
The group has led the implementation of the CIBERES Research Line on Pulmonary Hyper- tension. Within this line is worth mentioning the participation in an international multicenter clin- ical trial aimed at evaluating a new strategy for treatment of pulmonary hypertension with com- bined initial therapy (New Engl J Med. 2015. 373: 834-844). The group has also contributed to the preparation of the new european guidelines for the treatment of pulmonary hypertension and a guide-
Medicine. 2015;191(4):391-401.
MoLina r, MarraDes rM, augé JM, esCuDero JM, viñoLas n, reguart n et aL. Assessment of a Combined Panel of Six Serum Tumor Markers for Lung Cancer.American jour- nal of respiratory and critical care medicine. 2015;.
line on chronic thromboembolic pulmonary hyper- tension, in the program of Action and Monitoring Guidelines developed jointly by the Spanish College of Physicians and the Ministry of Health. The group is also involved in a collaborative project with indus- try on network management of patients with rare diseases, using pulmonary hypertension as a use case, funded by the National Program of Research, Development and Innovation Oriented to the Chal- lenges of the Society.
Institution: Hospital Clínic de Barcelona
Contact: Villarroel, 170. 08036 Barcelona · Tel.: 93 227 57 47 · E.mail: [email protected]
Web: http://www.idibaps.org/research/604/physiopathological-mechanisms-of-respiratory-illnesses
CIBERES I Annual report 2015 I 47